Upadacitinib for alopecia areata

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 25 Aug 2023: Trial registered, NCT06012240
  2. 11 Oct 2023: Trial started, NCT06012240
  3. 16 Jun 2025: Trial registered, NCT07023302
  4. 19 Jun 2025: Trial started, NCT07023302
  5. 19 Aug 2026: Trial registered, NCT07772492
  6. 24 Aug 2026: Trial started, NCT07772492

The trials

NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

State
Under way
Phase
Phase 3
People
1,500 planned
Started
11 Oct 2023
Primary completion
Apr 2030
Arms
Study 1: Group 1 Upadacitinib Dose A, Study 1: Group 2 Upadacitinib Dose B, Study 2: Group 1 Upadacitinib Dose A, Study 2: Group 2 Upadacitinib Dose B, Study 3: Group 1 Upadacitinib Dose B (SALT > 20), Study 3: Group 2 Upadacitinib Dose A (SALT ≤ 20), Study 3: Group 3 Upadacitinib Dose B (Non-Sustained), Study 3: Group 4 Upadacitinib Dose B (Sustained), Study 3: Group 5 Upadacitinib Dose A (Sustained), Study 4: Group 1 Upadacitinib Dose A, Study 4: Group 2 Upadacitinib Dose B, Study 4: Group 4 Upadacitinib Dose A, Study 4: Group 5 Upadacitinib Dose B
Results
None posted
Papers
doi:10.1001/jamadermatol.2026.2853
  1. 25 Aug 2023: Trial registered
  2. 11 Oct 2023: Trial started

NCT07023302: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata

State
Under way
Phase
Phase 3
People
125 taking part
Started
19 Jun 2025
Primary completion
Feb 2029
Arms
Group 1A: Upadacitinib Dose A, Group 2A: Upadacitinib Dose B, Group 1B: Upadacitinib Dose A, Group 2B: Upadacitinib Dose B, Period C: Upadacitinib Dose A Remains Dose A, Period C: Upadacitinib Dose A to Dose B, Period C: Upadacitinib Dose B Non-Sustained Responders, Period C: Upadacitinib Dose B Sustained Responders, Period C: Open-Label Upadacitinib Dose B
Results
None posted
  1. 16 Jun 2025: Trial registered
  2. 19 Jun 2025: Trial started

NCT07772492: A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata

State
Under way
Phase
Phase 3
People
300 planned
Started
24 Aug 2026
Primary completion
Mar 2032
Arms
Group 1A: Upadacitinib Dose 1, Group 2A: Upadacitinib Dose 2, Group 1B: Upadacitinib Dose 1, Group 2B: Upadacitinib Dose 2
Results
None posted
  1. 19 Aug 2026: Trial registered
  2. 24 Aug 2026: Trial started

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Placebo to upadacitinib.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.